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Summary box
What is already known?
 ► Receiving a correct diagnosis for HIV is critical for 
accessing treatment and prevention services. WHO 
publishes guidelines on HIV testing algorithms that 
maximise the likelihood of correctly determining 
one’s HIV status, yet global uptake of these recom-
mendations is unknown.
What are the new findings?
 ► Global uptake of WHO recommendations for HIV 
testing services are low, with only 26% of country 
policies in adherence.
What do the new findings imply?
 ► Adherence exists on a continuum, and there are 
several small steps countries could take that would 
greatly increase adherence and minimise the likeli-
hood of an incorrect diagnosis.
 ► More guidance from WHO is needed on new HIV 
testing technology and ways to simplify testing 
guidance.
AbSTrACT
Introduction Ensuring a correct and timely HIV diagnosis 
is critical. WHO publishes guidelines on HIV testing 
strategies that maximise the likelihood of correctly 
determining one’s HIV status. A review of national HIV 
testing policies in 2014 found low adherence to WHO 
guidelines. We updated this review to determine adherence 
to current recommendations.
Methods We conducted a comprehensive policy review 
through April 2018. We extracted data on HIV testing 
strategies, recommendations on HIV retesting prior to 
antiretroviral therapy (ART) initiation and pre- exposure 
prophylaxis (PrEP)- related HIV testing information. 
Descriptive analyses disaggregated by region were 
conducted to ascertain adherence to recommendations 
and to describe testing strategy characteristics.
results Of 91 policies included, 26% (n=24/91) adhered 
to WHO recommendations. Having a two- assay testing 
strategy to rule- in HIV infection as opposed to the 
recommended three- assay testing strategy was a major 
reason for non- adherence. Of 72 country policies providing 
sufficient information, 31% (n=22) recommended retesting 
for HIV prior to initiating ART. Of 25 countries and two 
regions reporting PrEP- related HIV testing guidelines, 
almost all recommended testing prior to initiating PrEP and 
every 3 months during PrEP use.
Conclusions Global adherence to WHO recommendations 
for HIV testing strategies have improved since 2014 but 
remain low. We found adherence existed on a continuum. 
Such a system provides insights into how countries can 
move towards adherence by making relatively minor 
changes to testing strategies. Guidance from WHO on 
the role of new HIV testing technologies within testing 
algorithms and identifying ways to simplify testing 
guidance is warranted.
InTroduCTIon
HIV testing services (HTS) are the critical 
gateway to accessing HIV- related care and 
treatment for those diagnosed as HIV posi-
tive and as a means to accessing preven-
tion services for those testing HIV negative. 
Despite its importance and recent testing 
scale- up to reach the ‘90-90-90’ targets set by 
UNAIDS, an estimated 21% of people living 
with HIV remain unaware of their serostatus.1
The HIV testing, treatment and preven-
tion landscape has recently undergone rapid 
change. For example, in 2015, WHO recom-
mended initiating antiretroviral therapy 
(ART) for all individuals living with HIV 
immediately on receiving an HIV- positive 
diagnosis, regardless of CD4 cell count (‘test 
and treat’).2 WHO also recommended the use 
of oral pre- exposure prophylaxis (PrEP) as an 
additional prevention option for individuals 
at substantial risk of HIV infection.2 Both 
recommendations bring new significance to 
HIV testing. With the test and treat approach, 
establishing correct HIV diagnoses becomes 
even more critical as an HIV- positive diagnosis 
becomes the sole criteria for initiating ART. 
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Providing lifelong ART to someone misdiagnosed as HIV 
positive has substantial emotional, financial and psycho-
social ramifications for the individual,3–5 as well as signifi-
cant reputational and cost implications for programmes.6 
Further, individuals initiating PrEP require HIV testing to 
confirm they are HIV negative and quarterly HIV testing 
during PrEP use.7 The WHO PrEP implementation tool 
suggests using the same HIV testing strategy, preferably 
the nationally verified testing algorithm, in the context of 
PrEP as recommended for HIV testing more generally.7
In recent years, in vitro diagnostic medical devices 
(IVDs) for detection of HIV have improved, making the 
diagnosis of HIV possible earlier in the course of infec-
tion.8 Quality- assured rapid diagnostic tests (RDTs) that 
detect antibodies to HIV are widely available, which 
enables HIV testing to be delivered at point of care. This 
same serological assay principle is also widely used in labo-
ratory settings. Fourth generation HIV antibody/antigen 
RDTs and immunoassays (IAs) can potentially detect HIV 
during acute infection, when antibodies to HIV are not 
yet detectable. Nucleic acid testing (NAT) technologies 
are becoming more simplified and robust, and therefore 
more accessible in many settings. Nucleic acid is the first 
marker of HIV infection that may be detected. Current-
ly,WHO does not have guidance relating to the suitability 
of NAT technologies for use in HIV testing strategies.
Despite these advances, uncertainty exists for any 
testing event as no single assay can provide a definitive 
HIV- positive diagnosis. Since 1997, WHO has recom-
mended countries adopt one of two testing strategies 
depending on the HIV prevalence in the population 
undergoing testing—including one for low (<5%) and 
one for high (≥5%) prevalence settings. When adhered 
to, and populated with assays meeting 99% sensitivity 
and 98% specificity, these testing strategies give a positive 
predictive value of ≥99%.9 National guidelines outlining 
HIV testing strategies are critical to ensure HIV testing is 
carried out accurately and timely. However, a 2014 review 
of national HIV testing policies from 48 countries found 
that only 17% of testing strategies adhered to WHO 
guidelines.10
In 2015, WHO released consolidated guidelines on 
HTS.11 These guidelines maintained previous recom-
mendations but added more guidance about HIV testing 
strategies and algorithms, including the order of assays to 
be performed based on sensitivity and specificity and an 
emphasis on national verification of testing algorithms. 
Additionally, the 2015 HTS guidelines highlighted the 
need to retest individuals newly diagnosed with HIV 
prior to starting ART, although this had previously been 
included in WHO guidance12 and information notes.13 
The need for retesting prior to ART initiation was high-
lighted due to reports of misdiagnosis14 15 and the global 
shift towards test and treat16—making it imperative to 
provide a correct diagnosis before the initiation of life- 
long treatment. Recent mathematical modelling has 
shown retesting prior to ART initiation to be a cost- saving 
quality measure in high and low HIV prevalence settings.6
Given the millions of HIV tests conducted annually, 
having testing strategies in place to minimise misdiag-
nosis while maintaining quality is critical. Prior to 2014 
and following the release of the 2015 HTS guidelines, 
WHO conducted dissemination events at regional and 
international conferences, provided technical support to 
countries and engaged partners and donors to support 
and promote implementation.
Considering the low uptake of WHO recommend 
testing strategies previously reported,11 we sought to 
update this review and to assess adherence to the 2015 
WHO recommendations on HIV testing strategies and 
quality measures, including retesting prior to ART initia-
tion. Additionally, in a subset of countries with guidance 
on HIV testing among PrEP users, we assessed the imple-
mentation of WHO recommended testing strategies 
among people initiating and/or taking PrEP.
MeTHodS
Search strategy
We undertook a comprehensive search of national 
policy documents pertaining to HTS through searching 
WHO repositories, governmental and non- governmental 
websites, and contacting country and regional experts 
through April 2018 (online supplementary file 1). We 
included any HTS- relevant policy document, including 
national guidelines on HIV testing, strategic plans related 
to HIV, integrated guidelines on the prevention, treat-
ment and care of HIV, and policies pertaining to PrEP. 
For inclusion, the policy must have reported on either 
a national HIV testing strategy and/or algorithm or an 
HIV testing strategy in the context of PrEP. There were no 
restrictions on language; however, policies in languages 
other than English had limited information extracted, 
with information on testing strategies prioritised. Date of 
policy publication was also not restricted. When policies 
for multiple years were identified for the same country, 
the most recent version containing relevant information 
on HTS strategies was included.
data extraction
Data were extracted from each policy by two independent 
reviewers into standardised coding forms (online supple-
mentary file 2). Differences between coders were resolved 
through consensus. To prevent misclassification, items 
were marked as ‘unclear’ during data extraction when 
lack of translation and/or lack of information prevented 
complete understanding. Data were extracted within the 
following categories: (1) policy information (publication 
year, location, HIV prevalence); (2) HTS strategy (serial/
parallel, number of assays, use of tie breaker to rule in 
HIV infection, mention of sensitivity and specificity in 
selecting assay order; use of WHO prequalified IVDs; 
assay names and types, sensitivity/specificity, mention 
of in- country verification; alignment or misalignment 
of testing strategy with WHO recommendations; (3) 
retesting before ART initiation; and (4) HIV testing in the 
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box 1 WHo guidelines for HIV testing strategies
WHo guidelines contain the following principles for HIV testing 
strategies:
 ► National testing strategies should conform to either the high (≥5%) 
or low (<5%) prevalence HIV testing strategy according to UNAIDS 
data on prevalence.130
 ► Testing specimens in a serial manner, meaning that the result of 
assay 1 is read and interpreted before deciding to proceed to assay 
2, and so on.
 ► Assay 3 should not be used as a tie breaker to rule in HIV infec-
tion. But assay 3 may be used across all settings to rule- out HIV 
infection.
 ► Each assay in the testing algorithm should have a sensitivity of 
≥99%, while assay 1 should have ≥98% specificity and assay 2 and 
assay 3≥99% specificity.
 ► Testing algorithms should be verified locally (eg, national or 
regional).
 ► Retest all people newly diagnosed with HIV, using the national veri-
fied testing algorithm, prior to ART initiation
Specifically for high prevalence settings (≥5%):
 ► Specimens reactive on assay 1 should be tested on another assay 
(assay 2).
 ► If the specimen is also reactive on assay 2, result should be report-
ed as HIV positive.
 ► If results between assay 1 and assay 2 are discrepant, both assays 
should be repeated.
 ► On repeat, if test results remain discrepant, assay 3 should be 
conducted.
 – If assay 3 is non- reactive (A1+, A2−, A3−), the result should be 
reported as HIV negative.
 – If assay 3 is HIV reactive (A1+, A2−, A3+), the result should be 
reported as HIV inconclusive and the individual should be retest-
ed after 14 days.
Specifically for low- prevalence countries (<5%):
 ► Specimens reactive on assay 1 should be tested on another assay 
(assay 2).
 ► Then, specimens reactive on assay 2 should be tested on another 
assay (assay 3).
 ► Specimens reactive on assay 3 should be reported as HIV positive.
 ► If results between assay 1 and assay 2 are discrepant (A1+, A2−), 
repeat both assays.
After repeat, if the assays are both non- reactive (A1−, A2−), the 
result should be reported as HIV negative.
After repeat, if the test results are still discrepant, the individual 
should be reported as HIV negative when assay 1 and assay 2 are 
either second or third generation assay principles. However, if assay 
1 is fourth generation assay, the individual should be reported as 
HIV inconclusive and retesting recommended after 14 days.
 ► After repeat, if assay 1 and assay 2 are both reactive (A1+, A2+), the 
specimen should be tested with assay 3. If assay 3 is reactive, the 
result should be reported as HIV positive. If assay 3 is non- reactive 
(A1+, A2+, A3−), the result should be reported as HIV inconclusive 
and retesting should be performed after 14 days.
context of PrEP (testing strategies/algorithms, frequency 
and description of testing).
Analysis
Adherence to WHO recommendations was assessed using 
criteria set forth in the 2012 WHO Guidance, ‘Service 
delivery approaches to HIV testing and counselling 
(HTC): A strategic policy framework’17 and expanded on 
in the 2015 WHO Guidance, ‘Consolidated guidelines on 
HIV testing services’ (box 1).11
Descriptive analyses, disaggregated by WHO region, 
were conducted to determine rates of adherence to 
WHO recommendations; use of serial or parallel testing 
strategies; number, type, brand and prequalification 
status of assays used, and use of the assay 3 test result 
as a tie breaker to rule- in HIV infection. Analyses were 
conducted in Microsoft Excel and data were visualised 
using Tableau V.2018.
Categorisation
Each testing strategy was assessed for adherence to 
WHO guidance using the information available. When 
assigning adherence, reviewers assessed alignment with 
WHO criteria and listed primary reasons for misalign-
ment. Primary reasons for non- adherence were qualita-
tively assessed and divided into minor and major issues 
(Box 2). The major and minor categories were deter-
mined by consensus based on the severity of issues as 
they pertain to the potential for misdiagnosis, as well as 
cost and quality concerns. For example, parallel testing 
was classified as a ‘major issue’ because it is costlier than 
serial testing and leads to a greater number of discrepant 
results, thus contributing to other quality issues and 
further resource increases.
Categorisation of testing strategies included:
 ► Fully adherent: no minor or major issues identified.
 ► Mostly adherent: one minor issue identified.
 ► Somewhat not adherent: two or more minor issues 
identified.
 ► Not adherent: one or more major issues identified.
To determine the proportion of countries adherent to 
WHO recommendations for HIV testing, country policies 
categorised as ‘full adherent’ and ‘mostly adherent’ were 
considered adherent and those categorised as ‘some-
what not adherent’ or ‘not adherent’ were considered 
non- adherent.
reSulTS
National policy documents related to HTS were identi-
fied for 146 countries. Of these, 55 were excluded from 
analysis for (1) not containing specific information on 
HIV testing strategies (eg, no details on order of assays, 
assays used, or algorithm (n=34)) and (2) an inability 
to extract information due to translation issues (n=21). 
Of the remaining 91 policy documents, each contained 
at least one piece of required information, but only 
76 provided enough information to assess alignment 
with WHO HIV testing strategies. Twenty- seven policy 
documents contained information on PrEP- related HIV 
testing.
Of 91 countries providing data on HIV testing strat-
egies,18–108 32 were from the Africa region (AFRO), 11 
from Eastern Mediterranean region (EMRO), 14 from 
the European region (EURO), 16 from the region of the 
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box 2 Minor and major issues with HIV testing strategy/
algorithm non- adherence
Minor issues of non- adherence
 ► Performing unnecessary Assay 3 following repeated discrepant 
Assay 1/Assay 2 results in low prevalence settings (should have 
been ruled HIV- negative after second round of discrepant Assay 1/
Assay 2, or HIV- inconclusive if Assay 1 was 4th generation assay)
 ► Not repeating Assay 1/Assay 2 at all upon discrepant results, or 
not repeating Assay 1/Assay 2 immediately upon discrepant results 
(e.g., waiting 14 days instead)
 ► Not mentioning a specific Assay 3 but alluding to an additional as-
say performed at a laboratory
 ► Not using WHO prequalified diagnostics in testing algorithm
Major issues of non- adherenc
 ► Not having Assay 3 to resolve discrepant A1/A2 in high prevalence 
settings
 ► Using a parallel testing strategy
 ► Reporting an HIV- positive diagnosis based on reactive test results 
from only two assays in a low prevalence setting
 ► Using the result of Assay 3 as a tie- breaker to rule- in HIV infection
Figure 1 (A) Countries with HIV testing services policies identified and included in analysis (n=91). (B) Countries with policies 
identified containing information on HIV testing in the context of pre- exposure prophylaxis (n=27).
Americas (AMRO), 8 from the South- East Asia region 
(SEARO) and 10 from the Western Pacific region (WPRO; 
figure 1a). Countries contributing data accounted for 
the vast majority of Fast Track Countries identified by 
UNAIDS (n=26/30), which comprise 89% of new HIV 
infections globally.109
Regarding HIV testing in the context of PrEP, 25 
country policies21 22 43 45 51 68 72 75 84 88 90 95 99 110–120 and 2 
regional policies121 122 (from the European Union and 
Australia/New Zealand) were included, of which 14 
were from AFRO, 6 from EURO, 4 from AMRO, 2 from 
SEARO, and 1 from the WPRO (figure 1b).
Policy publication dates ranged from 2005 and 2018. 
Approximately 75% of included policies were published 
from 2013 to 2018. All policies related to HIV testing in 
the context of PrEP were published from 2016 onwards.
Adherence to HIV testing strategies
Overall, 26% (n=24/91) of national testing strate-
gies were either adherent or mostly adherent to WHO 
recommendations, and 57% (n=52/91) of strategies were 
non- adherent. The remaining 16% (n=15/91) did not 
contain enough information to determine adherence. In 
high HIV prevalence countries, 50% of policies (n=6/12) 
were adherent or mostly adherent, and the most common 
major reason for non- adherence was lack of an assay 3 to 
resolve discrepant assay 1 and assay 2 results.
In low- prevalence countries (n=79), 23% of national 
strategies (n=18/79) were adherent or mostly adherent, 
59% (n=47/79) were non- adherent and 18% (n=14/79) 
did not contain enough information to determine 
adherence. Among low- prevalence countries, the most 
common major reason for non- adherence was diag-
nosing HIV based on reactive results for only two assays 
(n=35/47).
When stratified by WHO region, SEARO had the 
highest rate of adherence (n=5/8, 63%), followed 
by EMRO (n=5/11, 45%) and AFRO (n=9/32, 28%; 
table 1; figure 2). AMRO had the lowest rate of compli-
ance (n=1/16, 6%), mostly due to testing strategies that 
reported HIV- positive diagnosis based on reactive results 
for only two assays. Online supplementary file 3 contains 
adherence information for all national policies contrib-
uting data.
When restricted to the subset of countries with poli-
cies included in the 2014 review that also had an updated 
policy available for the current review (n=21), the 
proportion adhering to WHO guidelines in 2014 was 
9.5% (n=2/21) compared with 38% in the current review 
(n=8/21). The majority of countries moving from non- 
adherence to adherence from 2014 to the present came 
from sub- Saharan Africa (n=5/7).
Characteristics of testing strategies and testing algorithms
Of included policies, 84% (n=76/91) used a serial testing 
strategy, 10% (n=9/91) used a testing strategy involving 
some element of parallel testing, and in 7% (n=6/91) 
it was unclear whether a serial or parallel testing 
strategy was used. Twenty- seven per cent of strategies 
(n=25/91) contained two assays, 58% contained three 
assays (n=53/91), 6% contained more than three assays 
(n=6/91) and in 8% (n=7/91) the number of assays used 
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Table 1 HIV testing strategy characteristics by WHO region
WHO regional office for Adherence to WHO rec, n (%)
Use of tie breaker,
N (%)
Retesting prior to ART, 
N (%)
Africa (n=32) 9 (28%) 6 (19%) 16 (50%)
Eastern Mediterranean (n=11) 5 (45%) 2 (18%) 4 (35%)
Europe (n=14) 3 (21%) 0 (0%) 0 (0%)
Americans and the Caribbean (n=16) 1 (6%) 5 (16%) 1 (6%)
Southeast Asia (n=8) 5 (63%) 1 (13%) 1 (13%)
Western Pacific (n=10) 1 (10%) 0 (0%) 0 (0%)
Figure 2 Adherence to WHO recommendations for HIV 
testing strategy by region. Adherence to WHO testing 
recommendations for each WHO region. Colour shows 
details about compliance categorisation (full adherence=no 
major or minor issues; mostly adherent=one minor issues; 
somewhat not adherent=two or more minor issues; not 
adherent=one or more major issues).
was unclear. In some cases, a third assay was not specified 
but was alluded to in referring specimens to a laboratory 
for further testing, although often the specifics of such 
referrals were unclear. For testing strategies containing 
more than three assays, often this occurred when testing 
strategies recommended that specimens be sent to a labo-
ratory after performing two assays, with multiple assays 
recommended on reaching the reference laboratory.
Few policies contained the specific testing algorithms 
used in testing strategies. Only 32% of policy documents 
(n=29/91) mentioned specific product names. Sixteen 
policies mentioned the need to verify the testing algo-
rithm or specified that laboratories should verify the 
algorithm, and only one national testing policy provided 
outcomes of the testing algorithm verification study 
itself. Of 29 policies including information on assays 
(ie, specific product names), all but one included WHO 
prequalified products.
Seventy per cent (n=64/91) of policies provided the 
assay types used, for example, RDT, IA and western blot-
ting. Of 64 policies reporting assay types, RDTs and IAs 
were most common. Thirty- one per cent (n=20/64) 
included western blotting as an option for either assay 2 
or assay 3 (most commonly assay 3) and 13% (n=8/64) 
included NAT as an option for assay 2 or assay 3. Use 
of western blotting was common in EURO, EMRO and 
AMRO. Several high- income and middle- income coun-
tries reported using NAT technologies.
Overall, 15% (n=14/91) of testing strategies used 
results of assay 3 as a tie breaker to rule- in HIV infection 
(table 1); however, three specified the use of western blot 
or NAT as assay 3 to rule- in HIV infection. Most cases 
of using assay 3 as a tie breaker to rule- in HIV infection 
occurred in AFRO, mostly from West and North Africa 
(50%, n=7/14), and AMRO (36%, n=5/14). Of note, 
several countries referred to assay 3 as a ‘tie breaker’ 
although it was used correctly, that is, to rule- out HIV 
infection.
other issues with HIV testing strategies
Several policies specified different testing strategies for 
the purposes of diagnosis and surveillance, which contra-
dicts WHO recommendations to use the same testing 
strategies for both purposes. Additionally, some policies 
contained testing strategies where the number of assays 
varied depending on certain circumstances, such as the 
availability of assay 3 and whether signs and symptoms 
of HIV infection are present. Several low- prevalence 
countries included a high- prevalence testing strategy 
when working with key populations and a separate low- 
prevalence testing strategy for the general population.
retesting prior to art initiation
Of 91 policies, 72 provided information on HIV retesting 
prior to starting ART (19 were excluded due to transla-
tion issues or for not having enough information). Of 72 
policies, 31% (n=22) required or recommended retesting 
prior to ART initiation, and 86% of these (19/22) were 
published after 2015. The majority of policies requiring 
retesting were from AFRO (73%, n=16/22). The 
remaining 49 policies either did not require retesting 
prior to ART or did not specify whether retesting was 
required. Some policies required only written proof of 
an HIV diagnosis prior to initiating ART and only recom-
mended retesting if written confirmation was unavail-
able. Two national strategies required retesting but used 
a parallel testing strategy as opposed to a serial testing 
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strategy for retesting, which differed from national 
policy. Other countries specified that retesting should 
be performed with a different specimen and a different 
testing provider, in alignment with WHO recommenda-
tions.
HIV testing in the context of PreP
Twenty- five national policies and two regional policies 
(from the European Union and Australia/New Zealand) 
contained information regarding HIV testing in the 
context of PrEP. Of 27 policies, almost all (n=24/27) 
recommended HIV testing occur at PrEP initiation and 
every 3 months while taking PrEP. The remaining three 
policies did not specify a schedule for HIV testing in 
the context of PrEP. Several policies additionally recom-
mended retesting for HIV after 1 month of PrEP use and 
then 3 months thereafter. Two policies did not specify a 
testing schedule for PrEP users. Only four policies explic-
itly stated that HIV testing in the context of PrEP should 
follow the national verified HIV testing algorithm. Other 
policies did not specify what testing strategy or algorithm 
should be used, and one policy outlined a testing strategy 
for PrEP initiators and PrEP users that differed from 
the national testing strategy. Specifically, in this policy if 
a potential PrEP user had a non- reactive fourth gener-
ation antibody/antigen assay but reported symptoms of 
acute infection, NAT testing was recommended. Several 
other countries emphasised the need to assess signs and 
symptoms of acute HIV infection prior to initiating PrEP, 
and if present, to defer PrEP initiation until reviewing 
the result of further testing. Many high- income countries 
stipulated the use of fourth generation antigen/antibody 
assay for PrEP users and cautioned against the use of 
oral fluid- based serological assays. Policies from several 
countries included specific information on PrEP in their 
ARV guidelines, but clarified that PrEP was still under 
consideration for use in the country and therefore not 
yet available. Online supplementary file 3 contains data 
on policies providing information on HIV testing in the 
context of PrEP.
dISCuSSIon
This review found that slightly over a quarter of countries 
are fully or mostly adherent to WHO HIV testing recom-
mendations and that one- third recommend retesting for 
HIV prior to ART initiation. We found improvements 
in national HIV testing policies’ adherence to WHO 
guidelines as compared with a global review conducted 
in 2014.10 Specifically, rates of using the result of assay 3 
as a tie breaker to rule- in HIV infection have declined. 
Additionally, a considerable proportion of HIV testing 
policies published after the 2015 WHO HTS recommen-
dations adopted policy changes to maintain alignment 
with global guidelines, including adding requirements to 
retest newly diagnosed HIV- positive individuals for HIV 
prior to ART initiation and to regularly test PrEP users for 
HIV in a schedule adherent to WHO recommendations.
Overall adherence remains low. High- prevalence 
countries had proportionally higher rates of adherence 
than low- prevalence countries. Notably, of 12 strategies 
for high- prevalence countries identified, several have 
recently fallen below the 5% prevalence threshold.1 As 
HIV prevalence continues to decline globally, countries 
currently using a high- prevalence strategy may need to 
switch to a low- prevalence strategy, which WHO recently 
began encouraging countries to do.123 124 Eventually 
moving all countries to a low- prevalence testing strategy 
requiring reactive results from three assays to confirm 
HIV infection might be needed. Additionally, several 
countries noted that while the national HIV prevalence 
is below 5%, prevalence among key populations (eg, sex 
workers, men who have sex with men) is high (>5%), and 
thus policies suggested using a high- prevalence strategy 
among key populations. However, in these cases, it is 
unclear how the testing facility and/or tester would be 
aware of someone’s membership in a key population that 
would warrant using a different testing strategy.
We found that determination of adherence was often 
not a clear distinction, and adherence was more accu-
rately defined using a continuum with several levels 
of gradation. Many policies contained strategies that 
were close to adhering but included minor deviations. 
Conversely, other countries outlined testing strategies 
that clearly contradicted WHO recommendations. As a 
result, a more nuanced categorisation scheme was devel-
oped. Using the continuum of adherence framework, 
making relatively minor changes to many strategies could 
greatly improve alignment.
There are several adaptations countries could under-
take within national testing strategies to improve adher-
ence. First and foremost, using IVDs that have been 
stringently assessed (such as by a founding member of 
the Global Harmonization Task Force or that are WHO 
prequalified) ensures the testing algorithm contains 
assays that have been assessed for quality, safety, and 
performance. Second, verifying the testing algorithm 
to ensure that assays do not share false reactive results 
would improve testing quality. A recent study assessing 
the performance of different testing algorithms across 
six sites in sub- Saharan Africa found suboptimal perfor-
mance of multiple RDTs with site- specific differences, 
thus highlighting the critical importance of verifying 
algorithms.125
We found that approximately 30% of HIV testing 
strategies used western blot and over 10% used NAT in 
testing algorithms. WHO recently released guidance 
encouraging countries to move away from using western 
blotting and line IAs in HIV testing algorithms in favour 
of simpler tests.124 126 Further guidance regarding the 
use of NAT in testing algorithms would be beneficial. 
For example, undetectable HIV viral load should not 
be used to rule out HIV infection as it is possible to be 
HIV positive with undetectable HIV viral load. There is 
a theoretical possibility that NAT may be used to rule in 
HIV infection, but clinical utility studies to support this 
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intended use are ongoing. Regarding HIV testing in the 
context of PrEP, the WHO PrEP implementation tool 
notes that using assays capable of identifying acute infec-
tion, such as NAT, where feasible may offer additional 
benefits as those seeking PrEP could be at heightened 
risk of having acute HIV infection.7 However, to date, 
WHO has not issued recommendations on the use of 
NAT in the context of PrEP.
The majority of non- adherence issues for low- 
prevalence settings centred on diagnosing HIV infection 
using only two assays. This deviation has the potential 
to increase the occurrence of misdiagnosis, particularly 
false- positive diagnosis. According to previous modelling 
by WHO, using reactive test results from two assays in 
low- prevalence settings would lead to reduced positive 
predictive value as low as 90.8% in settings where prev-
alence is 0.1%,9 well below the 99% positive predictive 
value recommended. In a population of one million 
people who are unaware of their HIV status, this could 
cause up to 100 individuals to be placed on ART who are 
HIV negative.
While correct use of assay 3 results was poor in low HIV 
prevalence settings, many policies included strategies 
that used assay 3 to resolve discrepant test results from 
the first two assays. Thus, changing the testing strategy 
so that an assay 3 is used to confirm HIV infection for 
individuals who are reactive on the first two assays may 
be feasible. Implementing this shift across settings would 
increase adherence with WHO recommendations from 
26% to approximately 50%.
For high- prevalence settings, the primary issue was not 
having an assay three to resolve discrepant results from 
the first two assays. While misdiagnosis in these scenarios 
is not of primary concern, lacking an assay 3 to resolve 
discrepancies leads to important missed opportunities 
to provide a definitive HIV- negative diagnosis to those at 
ongoing risk for HIV and offer PrEP if warranted. Adding 
an assay 3 to the testing strategy or putting in clear referral 
mechanisms to a laboratory that could conduct an assay 3 
is needed. For countries using an assay 3 inappropriately 
to rule in HIV infection, strategies could be altered to 
allow assay 3 to rule out HIV infection only.
Minor issues identified in strategies, such as unneces-
sarily using an assay 3 to resolve discrepant results from 
assay 1 and assay 2 or not repeating the first and second 
assays in case of discrepant results, if corrected, could 
improve efficiency and cost related to HIV testing.
Given the relatively low rates of adherence to WHO 
recommendations found in this review, more under-
standing of why countries choose or choose not to adopt 
WHO HIV testing recommendations is needed. Given 
the unique context, resources and processes that guide 
national policy formation, having more pragmatic data 
on these critical aspects could help inform future guide-
line development. Although we did not collect such data, 
our results highlight specific areas of potential inquiry, 
such as investigating why so many countries fail to use a 
third assay in their national testing strategies. A study of 
country adaptation of WHO guidelines for the preven-
tion of mother- to- child transmission of HIV found that 
factors such as perceived complexity, cost, equity and 
existing healthcare infrastructure all factored into policy 
decision- making.127 Such a study on countries’ develop-
ment of HIV testing strategies is warranted. Research is 
also needed to understand the effectiveness of WHO’s 
strategies for dissemination of HTS guidelines as it is 
possible that countries are unaware of the most recent 
changes to global recommendations.
The HIV testing strategies recommended by WHO 
require certain costs and resources. The overall perceived 
cost may be a barrier to widespread implementation of 
standardised HIV testing strategies. It is for this reason 
that WHO recommends a differentiated HTS delivery 
approach, including community- based testing via a ‘test 
for triage’ and HIV self- testing, which work to expand 
access to HIV testing while not compromising the need 
to have the full testing strategy available at all testing sites. 
Both a ‘test for triage’ and HIV self- testing offer a single 
RDT administered in a community setting with linkage 
available to facility- based testing for the confirmation of 
HIV diagnoses and to clinical care when needed.128 129
Strengths and limitations
This review identified HTS policy documents from over 
140 countries and analysed policies from over 90 coun-
tries. The review used robust searching methods and 
standardised, systemic data extraction. Despite the study 
team’s comprehensive efforts, it is possible that existing 
policy documents were not identified as only policies that 
were publicly available or received through government 
contacts and country offices via WHO were included. 
Additionally, because of the nature of the documents 
studied, this review used a non- automatized search 
strategy; nonetheless, we used keywords when possible, 
making the search strategy defined and repeatable.
Additionally, we did not ascertain country implementa-
tion of HTS policies. Countries might be implementing 
HIV testing strategies different from the ones outlined 
in official policy documents, thus having a non- adherent 
testing strategy as written policy with adherent imple-
mentation or vice versa. Although we did not include 
subnational policy documents, it is possible that decen-
tralisation has led to variations in testing strategies at 
the subnational level that were missed by this review. 
Few countries provided specific testing algorithms in 
national policy documents, which limited our ability 
to assess adherence with WHO recommendations on 
testing algorithms. Additionally, for several data collec-
tion points, including national/regional verification of 
testing algorithm, we were only able to assess whether 
a policy provided specific mention of a procedure for 
verification and not whether the verification actually 
occurred; it is possible procedures such as algorithm 
verification are occurring but are not being included in 
policy documents. Finally, the inability to translate all 
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policy documents was a limitation; when possible, trans-
lations of testing strategies were prioritised.
ConCluSIonS
Recent changes to the HIV prevention and treatment 
landscape, including ‘test and treat’ and PrEP availa-
bility, have elevated the importance of receiving a correct 
HIV diagnosis—both HIV positive and HIV negative. 
Following WHO recommendations for HIV testing strat-
egies, performing verification of testing algorithms, and 
using appropriate assays can ensure accurate HIV diag-
nosis in a cost- efficient and time- efficient manner. While 
this review found a significant proportion of countries not 
adhering to WHO recommendations, adherence existed 
on a continuum. Our findings suggest that many coun-
tries are moving in the direction of increasing adherence 
and these efforts must be supported and lead to imple-
mentation. It is imperative that this trend continues, and 
more countries adopt WHO recommendations to ensure 
quality HIV testing programmes, especially in regards 
to requiring HIV retesting prior to ART initiation and 
implementing HIV testing in accordance with national 
guidelines for PrEP users. Understanding reasons behind 
countries decisions to adopt or not adopt WHO recom-
mendations could help identify potential solutions. Ways 
to simplify the WHO testing guidance are warranted, 
such as moving to one HIV testing strategy for all settings.
Twitter Cheryl Johnson @ccasejohn
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